路易斯安那州因邮购Mifepristone而起诉FDA, 声称这违反了国家堕胎禁令和安全法。 Louisiana sues FDA over mail-order mifepristone, claiming it violates state abortion bans and safety laws.

路易斯安那州已对FDA提出诉讼, 罪名是2023年允许将miferistone邮寄给病人, 认为该政策允许州外供应商将堕胎药丸送到几乎所有堕胎都被禁止的州。 Louisiana has sued the FDA over its 2023 rule allowing mifepristone to be mailed to patients, arguing the policy enables out-of-state providers to send abortion pills into the state, where nearly all abortions are banned. 国家声称,该规则破坏其法律,构成安全风险,为强迫或未经授权堕胎提供便利,援引了涉及一名据称在胁迫下服用药物的妇女的案件。 The state claims the rule undermines its laws, poses safety risks, and facilitates forced or unauthorized abortions, citing a case involving a woman who allegedly took the drug under duress. 路易斯安那州寻求恢复个人处方要求, 断言FDA违反了行政程序法和康斯托克法. Louisiana seeks to reinstate an in-person dispensing requirement, asserting the FDA violated the Administrative Procedure Act and the Comstock Act. 该诉讼案由总检察长Liz Murrill领导,遵循以前的法律努力,包括对相关案件中的医生和一名母亲提起的刑事指控。 The lawsuit, led by Attorney General Liz Murrill, follows previous legal efforts and includes criminal charges against doctors and a mother in related cases. 美国食品药品管理局没有回应. The FDA has not responded.